Antifungal Trials: Progress, Approaches, New Targets, and Perspectives in Cryptococcosis

Peter G. Pappas

doi:10.1128/9781555816858.ch39

Chapter 39 : Antifungal Trials: Progress, Approaches, New Targets, and Perspectives in Cryptococcosis

Author: Peter G. Pappas¹

VIEW AFFILIATIONS HIDE AFFILIATIONS

Affiliations: 1: Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294–0006

Content Type: Monograph

Publication Year: 2011

Category: Clinical Microbiology; Fungi and Fungal Pathogenesis

Book DOI: 10.1128/9781555816858

Chapter DOI: 10.1128/9781555816858.ch39

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:

Antifungal Trials: Progress, Approaches, New Targets, and Perspectives in Cryptococcosis, Page 1 of 2

< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555816858/9781555815011_Chap39-1.gif /docserver/preview/fulltext/10.1128/9781555816858/9781555815011_Chap39-2.gif

Abstract:

This chapter briefly describes the history of treatment for CNS cryptococcosis and discusses novel approaches to therapy with traditional agents, the newer antifungal agents, experimental agents, and the potential role of immunotherapy. The availability of fluconazole, itraconazole, the lipid formulations of amphotericin B, and the expanded spectrum triazoles provided additional options in the antifungal armamentarium. There are several newer antifungal agents that could offer significant advantages over more traditional agents. Specifically, three new triazoles, voriconazole, posaconazole, and isavuconazole, demonstrate excellent in vitro activity against most strains of clinically relevant Cryptococcus species. Passive immunotherapy has been advocated as a potentially important adjunct to conventional antifungal therapy in the management of invasive mycoses. The hypothetical value of cryptococcal antigen removal from the infected host relates to its function as a virulence factor: cryptococcal antigen is known to inhibit leukocyte migration, promote cerebral edema, promote cytokine dysregulation, induce T-lymphocyte secretion of immunosuppressive molecules, and induce the shedding of L-selectin. There are good data supporting the role of adjuvant corticosteroids in the early management of bacterial meningitis, and this has become a standard approach to patients with proven or suspected disease. Tacrolimus demonstrates synergistic activity with several antifungals including bafilomycin A (an experimental agent), caspofungin, and fluconazole. In the developed world, cryptococcosis in transplantation represents a large and inadequately studied complication among transplant recipients.

Citation: Pappas P. 2011. Antifungal Trials: Progress, Approaches, New Targets, and Perspectives in Cryptococcosis, p 527-536. In Heitman J, Kozel T, Kwon-Chung K, Perfect J, Casadevall A (ed), Cryptococcus. ASM Press, Washington, DC. doi: 10.1128/9781555816858.ch39

Key Concept Ranking

Antifungal Agents: 0.48241246
Fatty Acid Synthase: 0.45609546

0.48241246

Highlighted Text: Show | Hide

Full text loading...

References

/content/book/10.1128/9781555816858.ch39

1. Aberg,, J. A.,, R. W. Price,, D. M. Heeren, and B. Bredt. 2002. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J. Infect. Dis. 185: 1179– 1182.

2. Appelbaum, E., and, S. Shtokalko. 1957. Cryptococcus meningitis arrested with amphotericin B. Ann. Intern. Med. 47: 346– 351.

3. Baddour, L. M.,, J. R. Perfect, and, L. Ostrosky-Zeichner. 2005. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin. Infect. Dis. 40(Suppl. 6): S409– S413.

4. Bennett,, J. E.,, W. E. Dismukes,, R. J. Duma,, G. Medoff,, M. A. Sande,, H. Gallis,, J. Leonard,, B. T. Fields,, M. Bradshaw,, H. Haywood,, Z. A. McGee,, T. R. Cate,, C. G. Cobbs,, J. F. Warner, and, D. W. Alling. 1979. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N. Engl. J. Med. 301: 126– 131.

5. Bicanic,, T.,, G. Meintjes,, R. Wood,, M. Hayes,, K. Rebe,, L. G. Bekker, and T. Harrison. 2007. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin. Infect. Dis. 45: 76– 80.

6. Bicanic,, T.,, C. Muzoora,, A. E. Brouwer,, G. Meintjes,, N. Longley,, K. Taseera,, K. Rebe,, A. Loyse,, J. Jarvis,, L. G. Bekker,, R. Wood,, D. Limmathurotsakul,, W. Chierakul,, K. Stepniewska,, N. J. White,, S. Jaffar, and, T. S. Harrison. 2009. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin. Infect. Dis. 49: 702– 709.

7. Bicanic,, T.,, R. Wood,, R, G. Meintjes,, K. Rebe,, A. Brouwer,, A. Loyse,, L. G. Bekker,, S. Jaffar, and T. Harrison. 2008. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin. Infect. Dis. 47: 123– 130.

8. Blackie, J. D.,, G. Danta,, T. Sorrell, and, P. Collignon. 1985. Ophthalmological complications of cryptococcal meningitis. Clin. Exp. Neurol. 21: 263– 270.

9. Blankenship, J. R.,, N. Singh,, B. D. Alexander, and, J. Heitman. 2005. Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens. J. Clin. Microbiol. 43: 464– 467.

10. Bozzette,, S. A.,, R. A. Larsen,, J. Chiu,, M. A. Leal,, J. Jacobsen,, P. Rothman,, P. Robinson,, G. Gilbert,, J. A. McCutchan,, J. Tilles,, J. M. Leedom, and, D. D. Richman. 1991. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. The California Collaborative Treatment Group. N. Engl. J. Med. 324: 580– 584.

11. Brouwer,, A. E,, A. Rajanuwong,, W. Chierakul,, G. E. Griffin,, R. A. Larsen,, N. J. White, and, T. J. Harrison. 2004. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363: 1764– 1767.

12. Casadevall,, A.,, W. Cleare,, M. Feldmesser,, A. Glatman-Freedman,, D. L. Goldman,, T. R. Kozel,, N. Lendvai,, J. Mukherjee,, L. Pirofski,, J. Rivera,, A. L. Rosas,, M. D. Scharff,, P. Valadon,, K. Westin, and Z. Zhong. 1998. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 42: 1437– 1446.

13. Casadevall,, A.,, A. Cassone,, F. Bistoni,, J. E. Cutler,, W. Magliani,, J. W. Murphy,, L. Polonelli, and L. Romani. 1998. Antibody and/or cellmediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? Med. Mycol. 36(Suppl 1): 95– 105.

14. Chayakulkeeree, M., and, J. R. Perfect. 2006. Cryptococcosis. Infect. Dis. Clin. N. Am. 20: 507– 544., v–vi.

15. Chen,, S.,, T. Sorrell,, G. Nimmo,, B. Speed,, B. Currie,, D. Ellis,, D. Marriott,, T. Pfeiffer,, D. Parr, and K. Byth. 2000. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. The Australasian Cryptococcal Study Group. Clin. Infect. Dis. 31: 499– 508.

16. Coker,, R. J.,, M. Viviani,, B. G. Gazzard,, B. DuPont,, H. D. Pohle,, S. M. Murphy,, J. Atouguia,, J. L. Champalimaud, and, J. R. Harris. 1993. Treatment of Cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS. 7: 829– 835.

17. Croft, S. L.,, K. Seifert, and, M. Duchene. 2003. Antiprotozoal activities of phospholipid analogues. Mol. Biochem. Parasitol. 126: 165– 172.

18. Cruz,, M. C.,, M. DelPoeta,, P. Wang,, R. Wenger,, G. Zenke,, V. F. Quesniaux,, N. R. Movva,, J. R. Perfect,, M. E. Cardenas, and J. Heitman. 2000. Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob, Agents Chemother. 44: 143– 149.

19. de Gans,, J.,, P. Portegies,, G. Tiessens,, M. E. Schattenkerk,, J. Karel,, C. J. van Boxtel,, J. R. van Ketel, and, J. Stam. 1992. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 6: 185– 190.

20. Del Poeta,, M.,, M. C. Cruz,, M. E. Cardenas,, J. R. Perfect, and J. Heitman. 2000. Synergistic antifungal activities of bafilomycin A, fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743–873) with calcineurin inhibitors FK506 and L-685, 818 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44: 739– 746.

21. Denning,, D. W.,, R. M. Tucker,, L. H. Hanson,, J. R. Hamilton, and, D. A. Stevens. 1989. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch. Intern. Med. 149: 2301– 2308.

22. Desmet, P.,, K. D. Kayembe, and, C. De Vroey. 1989. The value of cryptococcal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire. AIDS 3: 77– 78.

23. Dismukes,, W. E.,, G. Cloud,, H. A. Gallis,, T. M. Kerkering,, G. Medoff,, P. C. Craven,, L. G. Kaplowitz,, J. F. Fisher,, C. R. Gregg,, C. A. Bowles,, S. Shadomy,, A. M. Stamm,, R. B. Diasio,, L. Kaufman,, S. Soong, and, W. C. Blackwelder. 1987. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. NIAID Mycoses Study Group. N. Engl. J. Med. 317: 334– 341.

24. Dromer, F.,, S. Mathoulin,, B. Dupont,, O. Brugiere, and, L. Letenneur. 1996. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. The French Cryptococcosis Study Group. Clin. Infect. Dis. 22(Suppl 2): S154– S160.

25. Dromer, F.,, C. Bernede-Bauduin,, D. Guillemot, and, O. Lortholary. 2008. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE 3: E2870.

26. Dromer,, F.,, J. Salamero,, A. Contrepois,, C. Carbon,, and P. Yeni. 1987. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55: 742– 748.

27. Ecevit,, I. Z.,, C. J. Clancy,, I. M. Schmalfuss, and, M. H. Nguyen. 2006. The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin. Infect. Dis. 42: 1443– 1447.

28. Gordon, M. A. 1963. Synergistic serum therapy of systemic mycoses. Mycopathologia 19: 150.

29. Gordon, M. A., and, E. Lapa. 1964. Serum protein enhancement of antibiotic therapy in cryptococcosis. J. Infect. Dis. 114: 373– 378.

30. Gordon, M. A., and, A. Casadevall. 1995. Serum therapy for cryptococcal meningitis. Clin. Infect. Dis. 21: 1477– 1479.

31. Graybill,, J. R.,, J. Sobel,, M. Saag,, C. van der Horst,, W. Powderly,, G. Cloud,, L. Riser,, R. Hamill, and W. Dismukes. 2000. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin. Infect. Dis. 30: 47– 54.

32. Grinsell,, M.,, L. C. Weinhold,, J. E. Cutler,, Y. Han, and, T. R. Kozel. 2001. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. J. Infect. Dis. 184: 479– 487.

33. Hage,, C. A.,, K. L. Wood,, H. T. Winer-Muram,, S. J. Wilson,, G. Sarosi, and, K. S. Knox. 2003. Pulmonary cryptococcosis after initiation of antitumor necrosis factor-alpha therapy. Chest 124: 2395– 2397.

34. Hamill,, R. J.,, J. D. Sobel,, W. El-Sadr,, P. C. Johnson,, J. R. Graybill,, K. Javaly, and, D. E. Barker. 2010. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin. Infect. Dis. 51: 225– 232.

35. Haubrich,, R. H.,, D. Haghighat,, S. A. Bozzette,, J. Tilles, and, J. A. McCutchan. 1994. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group. J. Infect. Dis. 170: 238– 242.

36. Husain, S.,, M. M. Wagener, and, N. Singh. 2001. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg. Infect. Dis. 7: 375– 381.

37. Ivanovska, N. 2003. Phospholipases as a factor of pathogenicity in microorganisms. J. Mol. Catalysis B: Enzymatic 22: 357– 361.

38. Johnson, L. B., and, C. A. Kauffman. 2003. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36: 630– 637.

39. Joly, V.,, L. Saint-Julien,, C. Carbon, and, P. Yeni. 1994. In vivo activity of interferon-γ in combination with amphotericin B in the treatment of experimental Cryptococcosis. J. Infect. Dis. 170: 1331– 1334.

40. Kesson,, A. M.,, M. C. Bellemore,, T. J. O’Mara,, D. H. Ellis, and, T. C. Sorrell. 2009. Scedosporium prolificans osteomyelitis in an immunocompromised child treated with a novel agent, hexadecylphosphocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin. Infect. Dis. 48: 1257– 1261.

41. Kontoyiannis,, D. P.,, R. E. Lewis,, B. D. Alexander,, O. Lortholary,, F. Dromer,, K. L. Gupta,, G. T. John,, R. Del Busto,, G. B. Klintmalm,, J. Somani,, G. M. Lyon,, K. Pursell,, V. Stosor,, P. Munoz,, A. P. Limaye,, A. C. Kalil,, T. L. Pruett,, J. Garcia-Diaz,, A. Humar,, S. Houston,, A. A. House,, D. Wray,, S. Orloff,, L. A. Dowdy,, R. A. Fisher,, J. Heitman,, N. D. Albert,, M. M. Wagener, and N. Singh. 2008. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob. Agents Chemother. 52: 735– 738.

42. Kovacs,, J. A.,, A. A. Kovacs,, M. Polis,, W. C. Wright,, V. J. Gill,, C. U. Tuazon,, E. P. Gelmann,, H. C. Lane,, R. Longfield,, G. Overturf,, A. M. Macher,, A. S. Fauci,, J. E. Parrillo,, J. E. Bennett, and H. Masur. 1985. Cryptococcosis in the acquired immunodeficiency syndrome. Ann. Int. Med. 103: 533– 538.

43. Larsen,, R. A.,, S. A. Bozzette,, B. E. Jones,, D. Haghighat,, M. A. Leal,, D. Forthal,, M. Bauer,, J. G. Tilles,, J. A. Mc-Cutchan, and, J. M. Leedom. 1994. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 19: 741– 745.

44. Larsen, R. A.,, M. A. Leal, and, L. S. Chan. 1990. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann. Intern. Med. 113: 183– 187.

45. Larsen,, R. A.,, P. G. Pappas,, J. Perfect,, J. A. Aberg,, A. Casadevall,, G. A. Cloud,, R. James,, S. Filler, and, W. E. Dismukes. 2005. Phase I evaluation of the safety and pharmacokinetics of murine-derived anti-cryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. The NIAID Mycoses Study Group. Antimicrob. Agents Chemother. 49: 952– 958.

46. Lendvai,, N.,, A. Casadevall,, Z. Liang,, D. L. Goldman,, J. Mukherjee, and L. Zuckier. 1998. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J. Infect. Dis. 177: 1647– 1659.

47. Lesho, E. 2006. Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Rev. Anti. Infect. Ther. 4: 469– 478.

48. Longley,, N.,, C. Muzoora,, K. Taseera,, J. Mwesigye,, J. Rwebembera,, A. Chakera,, E. Wall,, I. Andia,, S. Jaffar, and, T. S. Harrison. 2008. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin. Infect. Dis. 47: 1556– 1561.

49. Lortholary,, O.,, A. Fontanet,, N. Memain,, A. Martin,, K. Sitbon, and F. Dromer. 2005. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 19: 1043– 1049.

50. Lortholary,, O.,, F. Dromer,, S. Mathoulin-Pelissier,, C. Fitting,, L. Improvisi,, J. Cavaillon, and B. Dupont. 2001. Immune mediators in cerebrospinal fluid during cryptococcosis are influenced by meningeal involvement and human immunodeficiency virus serostatus. The French Cryptococcosis Study Group. J. Infect. Dis. 183: 294– 302.

51. Lutz, J. E.,, K. V. Clemons, and, D. A. Stevens. 2000. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J. Antimicrob. Chemother. 46: 437– 442.

52. Menichetti,, F.,, M. Fiorio,, A. Tosti,, G. Gatti,, M. B. Pasticci,, F. Miletich,, M. Marroni,, D. Bassetti, and S. Pauluzzi. 1996. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 22: 838– 840.

53. Mitchell,, D. H.,, T. C. Sorrell,, A. M. Allworth,, C. H. Heath,, A. R. McGregor,, K. Papanaoum,, M. J. Richards, and T. Gotlieb. 1995. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin. Infect. Dis. 20: 611– 616.

54. Mody, C. H.,, G. B. Toews, and, M. F. Lipscomb. 1988. Cyclosporin A inhibits the growth of Cryptococcus neoformans in a murine model. Infect. Immun. 56: 7– 12.

55. Mody, C. H.,, G. B. Toews, and, M. F. Lipscomb. 1989. Treatment of murine cryptococcosis with cyclosporin-A in normal and athymic mice. Am. Rev. Respir. Dis. 139: 8– 13.

56. Mukherjee, J.,, M. Feldmesser,, M. D. Scharff, and, A. Casadevall. 1995. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Antimicrob. Agents Chemother. 39: 1398– 1405.

57. Mukherjee, J.,, M. D. Scharff, and, A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60: 4534– 4541.

58. Mukherjee, J.,, L. Zuckier,, M. D. Scharff, and, A. Casadevall. 1994. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob. Agents Chemother. 38: 580– 587.

59. Mussini,, C.,, P. Pezzotti,, J. M. Miro,, E. Martinez,, J. C. de Quiros,, P. Cinque,, V. Borghi,, A. Bedini,, P. Domingo,, P. Cahn,, P. Bossi,, A. de Luca,, A. A. Monforte,, M. Nelson,, N. Nwokolo,, S. Helou,, R. Negroni,, G. Jacchetti,, S. Antinori,, A. Lazzarin,, A. Cossarizza,, R. Esposito,, A. Antinori, and, J. A. Aberg. 2004. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin. Infect. Dis. 38: 565– 571.

60. Newton,, P. N.,, L. H. Thai,, N. Q. Tip,, J. M. Short,, W. Chierakul,, A. Rajanuwong,, P. Pitisuttithum,, S. Chasombat,, B. Phonrat,, W. Maek-A-Nantawat,, R. Teaunadi,, D. G. Lalloo, and, N. J. White. 2002. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin. Infect. Dis. 35: 769– 772.

61. Odom,, A.,, S. Muir,, E. Lim,, D. L. Toffaletti,, J. Perfect, and J. Heitman. 1997. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J. 16: 2576– 2589.

62. Pachl,, J.,, P. Svoboda,, F. Jacobs,, K. Vandewoude,, B. van der Hoven,, P. Spronk,, G. Masterson,, M. Malbrain,, M. Aoun,, J. Garbino,, J. Takala,, L. Drgona,, J. Burnie, and R. Matthews. 2006. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. The Mycograb Invasive Candidiasis Study Group. Clin. Infect. Dis. 42: 1404– 1413.

63. Pappas,, P. G.,, B. D. Alexander,, D. R. Andes,, S. Hadley,, C. A. Kauffman,, A. Freifeld,, E. J. Anaissie,, L. Brumble,, L. Herwaldt,, J. Ito,, D. P. Kontoyiannis,, G. M. Lyon,, K. A. Marr,, V. A. Morrison,, B. J. Park,, T. Patterson,, T. M. Perl,, R. A. Oster,, M. Schuster,, R. Walker,, T. J. Walsh,, K. A. Wannemuehler, and, T. M. Chiller. 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50: 1101– 1111.

64. Pappas,, P. G.,, B. Bustamante,, E. Ticano,, R. J. Hamill,, P. C. Johnson,, A. Reboli,, J. Aberg,, R. Hasbun, and H. Hsu. 2004. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J. Infect. Dis. 189: 2185– 2191.

65. Pappas,, P. G.,, P. Chetchotisakd,, R. A. Larsen,, W. Manosuthi,, M. I. Morris,, T. Anekthananon. S. Sungkanuparph,, K. Supparatpinyo,, T. L. Nolen,, L. O. Zimmer,, A. S. Kendrick,, P. Johnson,, J. D. Sobel, and, S. G. Filler. 2009. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin. Infect. Dis. 48: 1775– 1783.

66. Pappas,, P. G.,, J. R. Perfect,, G. A. Cloud,, R. A. Larsen,, G. A. Pankey,, D. J. Lancaster,, H. Henderson,, C. A. Kauffman,, D. W. Haas,, M. Saccente,, R. J. Hamill,, M. S. Holloway,, R. M. Warren, and, W. E. Dismukes. 2001. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis. 33: 690– 699.

67. Park,, B. J.,, K. A. Wannemuehler,, B. J. Marston,, N. Govender,, P. G. Pappas, and, T. M. Chiller. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525– 530.

68. Perfect,, J. R.,, K. A. Marr,, T. J. Walsh,, R. N. Greenberg,, B. DuPont,, J. de la Torre-Cisneros,, G. Just-Nubling,, H. T. Schlamm,, I. Lustar,, A. Espinell-Ingroff, and E. Johnson. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36: 1122– 1131.

69. Perfect,, J. R.,, W. E. Dismukes,, F. Dromer,, D. L. Goldman,, J. R. Graybill,, R. J. Hamill,, T. S. Harrison,, R. A. Larsen,, O. Lortholary,, M. H. Nguyen,, P. G. Pappas,, W. G. Powderly,, N. Singh,, J. D. Sobel, and, T. C. Sorrell. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50: 291– 322.

70. Pfaller,, M. A.,, J. Zhang,, S. A. Messer,, M. E. Brandt,, R. A. Hajjeh,, C. J. Jessup,, M. Tumberland,, E. K. Mbidde, and, M. A. Ghannoum. 1999. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob. Agents Chemother. 43: 169– 171.

71. Pietrella, D.,, T. R. Kozel,, C. Monari,, F. Bistoni, and, A. Vecchiarelli. 2001. Interleukin-12 counterbalances the deleterious effect of human immunodeficiency virus type 1 envelope glycoprotein gp120 on the immune response to Cryptococcus neoformans. J. Infect. Dis. 183: 51– 58.

72. Pitisuttithum,, P.,, R. Negroni,, J. R. Graybill,, B. Bustamante,, P. Pappas,, S. Chapman,, B. S. Hare, and, C. J. Hardalo. 2005. Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. 56: 745– 755.

73. Pitisuttithum,, P.,, S. Tansuphasawadikul,, A. J. Simpson,, P. A. Howe, and, N. J. White. 2001. A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J. Infect. 43: 226– 233.

74. Powderly,, W. G.,, G. A. Cloud,, W. E. Dismukes, and, M. S. Saag. 1994. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 18: 789– 792.

75. Powderly,, W. G.,, M. S. Saag,, G. A. Cloud,, P. Robinson,, R. D. Meyer,, J. M. Jacobson,, J. R. Graybill,, A. M. Sugar,, V. J. McAuliffe,, S. E. Follansbee,, C. U. Tuazon,, J. J. Stern,, J. Feinberg,, R. Hafner, and, W. E. Dismukes. 1992. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N. Engl. J. Med. 326: 793– 798.

76. Raad,, I. I.,, J. R. Graybill,, A. B. Bustamante,, J. R. Graybill,, R. Hare,, G. Corcoran, and, D. P. Kontoyiannis. 2006. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin. Infect. Dis. 42: 1726– 1734.

77. Rex,, J. H.,, R. A. Larsen,, W. E. Dismukes,, G. A. Cloud, and, J. E. Bennett. 1993. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine 72: 207– 224.

78. Robinson,, P. A.,, M. Bauer,, M. A. Leal,, S. G. Evans,, P. D. Holtom,, D. M. Diamond,, J. M. Leedom, and, R. A. Larsen. 1999. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 28: 82– 92.

79. Saag,, M. S.,, G. A. Cloud,, J. R. Graybill,, J. D. Sobel,, C. U. Tuazon,, P. C. Johnson,, W. J. Fessel,, B. L. Moskovitz,, B. Wiesinger,, D. Cosmatos,, L. Riser,, C. Thomas,, R. Hafner, and, W. E. Dismukes. 1999. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group. Clin. Infect. Dis. 28: 291– 296.

80. Saag,, M. S.,, R. J. Graybill,, R. A. Larsen,, P. G. Pappas,, J. R. Perfect,, W. G. Powderly,, J. D. Sobel, and, W. E. Dismukes. 2000. Practice guidelines for the management of cryptococcal disease. Clin. Infect. Dis. 30: 710– 718.

81. Saag,, M. S.,, W. G. Powderly,, G. A. Cloud,, P. Robinison,, M. H. Grieco,, P. K. Sharkey,, S. E. Thompson,, A. M. Sugar,, C. U. Tuazon,, J. F. Fisher,, N. Hyslop,, J. M. Jacobson,, R. Hafner, and, W. E. Dismukes. 1992. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N. Engl. J. Med. 326: 83– 89.

82. Santangelo,, S.,, H. Zoellner,, T. C. Sorrell,, C. Wilson,, C. Donald,, J. Djordjevic,, Y. Shounan, and L. Wright. 2004. Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect. Immun. 72: 2229– 2239.

83. Schaars,, C. F.,, G. A. Meintjes,, C. Morroni,, F. A. Post, and G. Maartens. 2006. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect. Dis. 6: 118.

84. Shaariah, W.,, Z. Morad, and, A. B. Suleiman. 1992. Cryptococcosis in renal transplant recipients. Transplant Proc. 24: 1898– 1899.

85. Shapiro, L. L., and, J. B. Neal. 1925. Torula meningitis. Arch. Neurol. Psych. 13: 174– 190.

86. Sharkey,, P. K.,, J. R. Graybill,, E. S. Johnson,, S. G. Hausrath,, R. B. Pollard,, A. Kolokathis,, D. Mildvan,, P. Fan-Havard,, R. H. K. Eng,, T. F. Patterson,, J. C. Pottage,, M. S. Simberkoff,, J. Wolf,, R. D. Meyer,, R. Gupta,, L. W. Lee, and, D. S. Gordon. 1996. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 22: 315– 321.

87. Singh,, N.,, B. D. Alexander,, O. Lortholary,, F. Dromer,, K. L. Gupta,, G. T. John,, K. J. Pursell,, P. Munoz,, G. B. Kintmalm,, V. Stosor,, R. Del Busto,, A. P. Limaye,, A. C. Kalil,, T. L. Pruett,, J. Garcia-Diaz,, A. Humar,, S. Houston,, A. A. House,, D. Wray,, S. Orloff,, L. A. Dowdy,, R. A. Fisher,, J. Heitman,, M. M. Wagener, and S. Husain. 2007. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J. Infect. Dis. 195: 756– 764.

88. Singh,, N.,, O. Lortholary,, B. D. Alexander,, K. L. Gupta,, G. T. John,, K. J. Pursell,, P. Munoz,, G. B. Kintmalm,, V. Stosor,, R. Del Busto,, A. P. Limaye,, J. Somani,, M. Lyon,, S. Houston,, A. A. House,, T. L. Pruett,, S. Orloff,, A. Humar,, L. A. Dowdy,, J. Garcia-Diaz,, R. A. Fisher,, A. C. Kalil,, J. Heitman, and S. Husain. 2005. Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infection. Transplantation 80: 1033– 1039.

89. Singh,, N.,, O. Lortholary,, B. D. Alexander,, K. L. Gupta,, G. T. John,, K. J. Pursell,, P. Munoz,, G. B. Kintmalm,, V. Stosor,, R. Del Busto,, A. P. Limaye,, J. Somani,, M. Lyon,, S. Houston,, A. A. House,, T. L. Pruett,, S. Orloff,, A. Humar,, L. A. Dowdy,, J. Garcia-Diaz,, R. A. Fisher,, A. C. Kalil,, J. Heitman, and S. Husain. 2005. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin. Infect. Dis. 40: 1756– 1761.

90. Singh,, S. D.,, N. Robbins,, A. K. Zaas,, W. A. Schell,, J. R. Perfect, and, L. E. Cowen. 2009. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog. 5: E1000532.

91. Steinbach,, W. J.,, J. L. Reedy,, R. A. Cramer,, J. R. Perfect, and J. Heitman. 2007. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nature Rev. 5: 418– 430.

92. Stevens, D. A. 1998. Combination immunotherapy and antifungal chemotherapy. Clin. Infect. Dis. 26: 1266– 1269.

93. Stevens, D. A.,, E. Brummer, and, K. V. Clemons. 2006. Interferon-γ as an antifungal. J. Infect. Dis. 194: S33– S37.

94. Sun, H. Y.,, C. C. Hung, and, S. C. Chang. 2004. Management of cryptococcal meningitis with extremely high intracranial pressure in HIV-infected patients. Clin. Infect. Dis. 38: 1790– 1792.

95. Sun,, H. Y.,, M. M. Wagener,, and N. Singh. 2009. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin. Infect. Dis. 48: 1566– 1576.

96. Taber, K. W. 1937. Torulosis in man. JAMA 108: 1405– 1406.

97. Tansuphaswadikul,, S.,, W. Maek-a-Nantawat,, B. Phonrat,, L. Boonpokbn,, A. G. Mctm, and P. Pitisuttithum. 2006. Comparison of one week with two week regimens of amphotericin B both followed by fluconazole in the treatment of cryptococcal meningitis among AIDS patients. J. Med. Assoc. Thai. 89: 1677– 1685.

98. Tassie,, J. M.,, L. Pepper,, C. Fogg,, S. Biraro,, B. Mayanja,, I. Andia,, A. Paugam,, G. Priotto, and D. Legros. 2003. Systematic screening of cryptococcal antigenemia in HIV-positive adults in Uganda. J. Acquir. Immune Defic. Syndr. 33: 411– 412.

99. Thompson,, G. R.,, N. P. Wiederhold,, A. W. Fothergill,, A. C. Vallor,, B. L. Wickes, and, T. F. Patterson. 2009. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 53: 309– 311.

100. van der Horst,, C. M.,, M. S. Saag,, G. A. Cloud,, R. J. Hamill,, J. R. Graybill,, J. D. Sobel,, P. C. Johnson,, C. U. Tuazon,, T. Kerkering,, B. L. Moskovitz,, W. G. Powderly, and, W. E. Dismukes. 1997. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. The NIAID Mycoses Study Group and AIDS Clinical Trials Group. N. Engl. J. Med. 337: 15– 21.

101. van Duin, D.,, W. Cleare,, O. Zaragoza,, A. Casadevall, and, J. D. Nosanchuk. 2004. Effects of voriconazole on Cryptococcus neoformans. Antimicrob. Agents Chemother. 48: 2014– 2020.

102. Vilchez, R. A.,, J. Fung, and, S. Kusne. 2002. Cryptococcosis in organ transplant recipients: an overview. Am. J. Transplant. 2: 575– 580.

103. White, M.,, C. Cirrincione,, A. Blevins, and, D. Armstrong. 1992. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J. Infect. Dis. 165: 960– 963.

104. Widmer,, F.,, L. C. Wright,, D. Obando,, R. Handke,, R. Ganendren,, D. H. Ellis, and, T. C. Sorrell. 2006. Hexadecylphosphocholine (miltefosine) has broadspectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob. Agents Chemother. 50: 414– 421.

105. Wiley, J. M.,, N. L. Seibel, and, T. J. Walsh. 2005. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr. Infect. Dis. J. 24: 167– 174.

106. Wu,, G.,, R. A. Vilchez,, B. Eidelman,, J. Fung,, R. Kormos, and S. Kusne. 2002. Cryptococcal meningitis: an analysis among 5521 consecutive organ transplant recipients. Transpl. Infect. Dis. 4: 183– 188.